Novartis Pharmaceuticals Canada has successfully negotiated with the pan-Canadian Pharmaceutical Alliance (pCPA) for the public reimbursement of PLUVICTO™ (lutetium (177Lu) vipivotide tetraxetan injection), a new treatment for prostate cancer. This milestone, announced on December 13, 2024, paves the way for broader access, though patients will still need to wait for inclusion in provincial and territorial formularies.
PLUVICTO™ targets prostate-specific membrane antigen (PSMA) in metastatic castration-resistant prostate cancer (mCRPC) patients who have already undergone other treatments. The therapy combines a targeting compound with a radioactive particle to deliver precision cancer treatment, potentially offering hope to those with limited options.
Healthcare professionals and patient advocacy groups view the agreement as a major step forward for patients, particularly those with advanced prostate cancer who have exhausted other treatments. Novartis is committed to working with local drug programs to ensure rapid access to this important therapy.
